3 potential takeover targets in obesity

Momentum is building to bring a next-generation weight loss drug to market, which could set up these three biotechs to strike a deal with a larger pharma.

By Kelly Bilodeau • June 8, 2026

BMS under pressure in schizophrenia; Summit/Akeso on a winning streak

While the large pharma’s new drug Cobenfy has stumbled in schizophrenia, it could find new life in Alzheimer’s disease

By PharmaVoice staff • June 5, 2026

Explore the Trendline➔

Artificial intelligence & machine learning

After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.

By PharmaVoice staff

GSK, Takeda and others notch key clinical wins in tough-to-treat diseases

From hepatitis B to melanoma, recent study results show innovative approaches are gaining ground.

By Kelly Bilodeau • June 5, 2026

Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?

While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.

By Kelly Bilodeau • June 4, 2026

When the ISS comes down, will its drug R&D be lost in space?

 As NASA prepares to bring its hallmark space lab back to Earth, a host of private companies are emerging to fill the gap.

By Meagan Parrish • June 3, 2026

As amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next

The Alzheimer’s pipeline is growing as drug developers put more emphasis on inflammation, tau and biomarkers.

By Kelly Bilodeau • June 2, 2026

AstraZeneca aims for a new blockbuster run in cardio disease

With a recent FDA nod for Baxfendy under its belt, AstraZeneca is looking to grow its prowess in cardio disease, weight management and beyond, according to a company exec.

By Alexandra Pecci • June 1, 2026

Can AI crack pharma’s drug repurposing goldmine?

With AI now capable of analyzing decades’ worth of data, FDA is pushing pharma to leverage its “enormous, untapped value” by repurposing drugs.

By Alivia Kaylor • May 29, 2026

Longevity science picks up steam in pharma

Fueled by multi-billion-dollar valuations and a deeper understanding of aging biology, the field is rapidly moving past the hype and into the clinic.

By Kelly Bilodeau • May 29, 2026

Vertex’s Journavx made history, but left a void in the pain space

The search is still on for an opioid alternative and many companies are betting on ion channel drugs to fill the gap.

By Kelly Bilodeau • May 28, 2026

The ‘secret sauce’ for hiring for biotech CEOs

Biotech company architect Stella Vnook shares her formula for finding the right chief executives.

By Alexandra Pecci • May 27, 2026

In Alzheimer’s, Bristol Myers sees big promise beyond amyloid

Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.

By Jacob Bell • May 27, 2026

Who’s winning pharma’s innovation race? The rankings are out.

While Eli Lilly reigns supreme, Idea Pharma’s annual R&D ranking reveals which other large pharmas are on the rise — and which are stumbling.

By Meagan Parrish • May 22, 2026

Big Pharma is gambling on specialized R&D. Will it pay off?

Large pharma companies are taking bigger swings on fewer targets, which can be a risky strategy.

By Kelly Bilodeau • May 20, 2026

Summer reads with unexpected lessons for biopharma leaders

From an inspiring rags-to-riches journey to a heroic rescue story at sea, here are a few books recommended by biopharma execs and what they can teach about leadership.

By Alexandra Pecci • May 19, 2026

Regeneron immunotherapy combo comes up short in melanoma trial

A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.

By Ben Fidler • May 19, 2026

Race intensifies to lead next wave of obesity drugs as trial results loom

As next-generation GLP-1 contenders rise, key readouts are on the way from Pfizer, Viking Therapeutics and Eli Lilly.

By Kelly Bilodeau • May 18, 2026

Sanofi’s vaccine bump; the new FDA commish

A look at how vaccine makers are scraping by, and at the incoming acting FDA head, Kyle Diamantas.

By PharmaVoice staff • May 15, 2026

Former Ovid CEO Dr. Jeremy Levin’s rallying cry for biotech

The long-time pharma exec is on a quest with a new book and bold message for biotech leaders and U.S. lawmakers.

By Meagan Parrish • May 15, 2026

FDA chief’s exit clouds already murky drug approvals

During Dr. Martin Makary’s tenure as commissioner, the FDA faced pushback over high-profile drug rejections for Replimune and UniQure.

By Kelly Bilodeau • May 14, 2026

India’s pharma industry is going global. But can it catch up to China?

A record  Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.

By Kelly Bilodeau • May 13, 2026

Why the FDA’s push for real-time clinical trials could favor Big Pharma

The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.

By Alivia Kaylor • May 13, 2026

Cancer, immunology startups lead latest wave of stealth exits

A handful of recently debuted biotechs reveal where drug R&D is headed next.

By Alexandra Pecci • May 11, 2026

Protein degraders gain speed as Arvinas scores landmark approval

Although excitement over the biotech’s “Protac” protein degrader is being tempered by narrower-than-expected clinical benefit, R&D in the field is heating up.

By Kelly Bilodeau • May 4, 2026

Revolution’s on a pancreatic cancer winning streak. What comes next for the biotech?

Results show a landmark change that could double survival rates in one of the most difficult oncology diagnoses, but there are still obstacles to overcome.

By Kelly Bilodeau • April 29, 2026